Abeona Therapeutics(US:ABEO)2026-03-10 13:42Summary of Abeona Therapeutics Conference Call Company Overview - Company: Abeona Therapeutics (NasdaqCM:ABEO) - Product: ZEVASKYN, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) Key Points Launch Progress - The launch of ZEVASKYN is progressing well, with the first patient treated in December 2025, following FDA approval in April 2025 [3][4] - Initial delays were due to assay optimization related to sterility testing, which has since been resolved [4][6][9] Assay Optimization - A false positive issue was identified with a rapid sterility assay, which has been addressed through optimization to reduce the likelihood of false positives [4][7][10] - The company is confident that the risk of false positives has been significantly minimized, although empirical evidence will be gathered from ongoing runs [10][12] Market Opportunity - The target patient population for ZEVASKYN is approximately 750 patients in the U.S. with moderate to severe RDEB, leading to an estimated total addressable market of about 1,500 treatment opportunities [16][17] - The urgency for treatment is heightened due to the risk of complications such as squamous cell carcinomas in these patients [17] Patient Journey - The patient journey from identification to treatment currently takes about 4-5 months, with expectations to reduce this timeframe as processes are streamlined [21][31] - The manufacturing time for the product is approximately 25 days once a biopsy is collected [22][31] Treatment Center Expansion - Abeona aims to activate 5-7 qualified treatment centers (QTCs) in 2026, with ongoing engagement from additional centers expressing interest [52][53] - Currently, two centers are actively treating patients, with plans to onboard more centers to increase patient throughput [27][47] Demand and Patient Identification - As of the call, 50 patients have been identified, with a high conversion rate expected due to the severity of their conditions [41][43] - The company is actively working to increase the number of patients treated as more centers come online and administrative processes improve [37][51] Capacity and Manufacturing - Current manufacturing capacity is 6 slots per month, with plans to ramp up to 10 slots in the second half of the year [57][59] - Long-term plans include the potential to double capacity to 20 slots, contingent on facility upgrades [61] Future Strategy - The company is focused on the successful launch of ZEVASKYN before discussing pipeline assets, with profitability expected in 2026 if treatment rates exceed three patients per month [67][69] - There is interest in expanding the use of ZEVASKYN for less severe patients and other applications, such as post-surgical treatment for pseudosyndactyly [62] Conclusion - Abeona Therapeutics is on track with the launch of ZEVASKYN, addressing initial challenges and focusing on expanding treatment capacity and patient access. The company is optimistic about achieving profitability in the near future as demand grows and operational efficiencies improve.